Intravenous vitamin C, often called IV-C, is a therapy where high doses of vitamin C are delivered directly into the bloodstream through an IV drip. Because the digestive system limits how much vitamin C can be absorbed by mouth, IV delivery allows much higher blood levels than pills or powders can achieve.
In cancer care, Intravenous high-dose Vitamin C was first used in the 1970’s with an initial observational study published by Ewan Cameron and Linus Pauling in 1976. The bulk of subsequent research has shown IV-C to be a supportive therapy, but not a cure for cancer. Nonetheless, it is widely used by integrative oncology providers and is considered a very important adjunctive treatment for patients fighting cancer.
Research on IVC in cancer care is still preliminary. Several small clinical trials, observational studies, and case reports have explored its use, most often alongside chemotherapy. Some studies have also looked at IVC with radiation therapy, androgen deprivation therapy, or on its own.
Overall, studies suggest IVC is generally well tolerated when properly screened and monitored. Some research has found improvements in symptoms such as fatigue, pain, nausea, appetite loss, and overall quality of life. Early findings also suggest possible benefits for treatment outcomes in certain cancers, including advanced pancreatic, ovarian, colorectal, and lung cancers.
More high-quality studies are needed to understand who is most likely to benefit, what dose is best, and whether IVC can meaningfully improve survival or disease control.
At high blood levels, vitamin C appears to act as a “pro-oxidant” as compared to lower (oral) doses which act as an “anti-oxidant”. This pro-oxidant activity is believed to be due to the generation of hydrogen peroxide around cancer cells. This creates oxidative stress that cancer cells are less able to manage than healthy cells. Vitamin C may also support collagen formation, inhibit enzyme pathways involved in cancer growth, reduce inflammation, interfere with tumor blood vessel formation, and support other immune functions.
IVC has a good safety profile and is well-tolerated for appropriately selected patients, but it is not suitable for everyone. It should not be used in people with kidney failure or G6PD deficiency. Extra caution is needed for people with a history of kidney stones, insulin-dependent diabetes, iron storage disorders, fluid overload conditions, or those taking warfarin.
Reported side effects are usually mild and uncommon, but may include thirst, dry mouth, increased urination, elevated blood pressure, diarrhea, nausea, fatigue, weakness, headache, dizziness, injection-site discomfort, vein irritation, swelling, or loss of appetite. The most frequent side effect seen is headache and jitteriness/dizziness which can be avoided by lowering the dose.
The vitamin C is mixed into sterile water along with magnesium for administration. An IV-line is established either in a peripheral vein in the hand or arm, or administered through a port or PICC line if the patient has one. Dosing varies based on patients’ tolerance which can be related to body size and sensitivity. Patients typically start at an initial dose of 20 grams and work up to 75-100 grams. Treatments are commonly given 1-3 times per week for several weeks to several months. Each infusion may take one to three hours, depending on the dose.
IVC is a promising supportive therapy in cancer care. For some people, it may help alleviate side effects or improve quality of life during or after treatment. Your naturopathic oncology specialist will perform proper screening, monitoring, and coordination with your cancer treatment to ensure safety. Treatments can be stopped at any time based on patient preference, but typically will be recommended to continue throughout your conventional treatment and will be stopped when you are back to your base-line of health.
